AlloSCT is a potentially curative procedure for haematological malignancies and marrow failure syndromes. However, unlike leukaemia and lymphoproliferative disorders, AlloSCT has yet to find its place in the clinical management of patients with multiple myeloma. AlloSCT in multiple myeloma is associated with a high procedurerelated mortality (TRM up to 35%) when full-intensity conditioning is used and only up to 36% of cases show long-term disease-free survival. The introduction of reduced intensity conditioning AlloSCT, more recently following an autologous SCT, has reduced the TRM to o20%, but there is an associated increased relapse risk. The use of donor lymphocyte infusions and novel biological agents (thalidomide, bortezomib), alone or together, can be effective in relapsed and even persistent disease post-AlloSCT. Thus, in pursuit of the putative graft-versus-myeloma effect, we need to consider the whole patient management pathway both preceding (depth of response to novel agents) and post-AlloSCT, to minimize the toxicity while harnessing the adoptive immunotherapy effect. This review sets out what we have learned to date from the clinical research studies in this area, examines concepts for improving the outcomes of AlloSCT and proposes a potential direction of clinical investigation to maximize the effect of AlloSCT in multiple myeloma.
Introduction
AlloSCT has been used in the management of leukaemia for several decades and has established its role in producing long-term remissions. In the context of multiple myeloma, compared with conventional therapies, AlloSCT induces the highest rate of remissions, including molecular remission, resulting in long-term disease-free survival in over 30% of patients. [1] [2] [3] However, it is associated with the highest rate of treatment-related mortality of all the interventions for multiple myeloma resulting from conditioning-related end-organ damage and the unwanted immunological toxicity of GVHD in addition to immune suppression-related opportunistic infection. 4 The effectiveness of AlloSCT results from the combination of high-dose chemotherapy and the adoptive immunotherapeutic effect of competent donor immune effector cells in eradicating the disease is established (graft-versusmyeloma effect (GvM)). The former aims to cytoreduce and is combined with autologous stem cell rescue as firstline therapy in suitably fit patients. 5, 6 However, ultimately all patients relapse. The GvM immunological effect, best shown by the use of donor lymphocyte infusions (DLI) to re-induce disease responses after relapse post-AlloSCT, though less potent than that seen with chronic myeloid leukaemia, significantly contributes to the disease-free survival effect noted with AlloSCT in multiple myeloma. 7, 8 The published evidence surrounding these two key issues in AlloSCT for multiple myeloma suggests that they are not mutually exclusive in their contribution to long-term disease-free survival in multiple myeloma, though the relevant contribution of each of these effects remains to be clarified. There is evidence that the method and degree of cytoreduction and the GvM effect contribute to longterm disease-free survival in multiple myeloma.
Therefore, the challenge for transplant physicians is how to harness the GvM effect while maintaining acceptable toxicity, and thus extending the spectrum of patients with multiple myeloma who would benefit from AlloSCT. This review describes the history behind AlloSCT in multiple myeloma, which informs us of current practice before viewing opportunities for the future.
Myeloma biology: impact on use of AlloSCT
Myeloablative or full-intensity AlloSCT in multiple myeloma can result in long-term disease-free survival in a significant minority of patients, but is controversial because of the procedure's high TRM and the definitive evidence of clear survival benefit. This high TRM is probably due to a combination of factors: particularly the generally more advanced age of patients, myeloma-related organ damage (in particular renal impairment), disease-associated immune dysfunction and infection risk owing to the effects of earlier treatment. The survival of patients with myeloma ranges from a few weeks to 420 years, but there is good evidence that the median survival of patients has increased over the last decade. [9] [10] [11] This has resulted from improvements in supportive care, the introduction of novel therapies and the increased use of high-dose therapy, which has made decision making for younger patients with an HLA-matched sibling donor even more difficult. Multiple myeloma has a median age at presentation of B70 years and only 15% of patients are aged o60 years, with the result that only a minority of patients are eligible for AlloSCT even when reduced-intensity conditioning (RIC) AlloSCT is included.
Analysis of prognostic factors is essential to compare outcomes within and between clinical trials and in particular to assess whether certain treatments such as AlloSCT or 'new agents' can overcome the effect of prognostic factors that would be associated with a poor outcome with conventional therapy. The International Staging System is considered to be the standard prognostic model and identifies three risk categories on the basis of levels of b 2 -microglobulin and albumin. 12 Cytogenetic and molecular genetic abnormalities have also been shown to be useful predictors of outcome. The presence of chromosome 13 deletion by conventional karyotyping and the t(4;14), t(14;16), t (14;20) , and deletion of 17p by FISH have been shown to confer an adverse outcome. [13] [14] [15] Gene expression profiling has also been used to define patients who are at 'high risk'. 16 However, the routine clinical use of these tests in selecting therapy for individual patients remains unproven. A number of groups have attempted to identify a high-risk group that do not appear to derive durable remissions from high dose therapy and have sought to investigate alternative strategies for these patients, including the use of AlloSCT.
AlloSCT in multiple myeloma-the history
The first AlloSCT for multiple myeloma was carried out in the early 1980s. In 1991, a retrospective analysis of EBMT (European Group for Blood and Marrow Transplantation) registry data with a median follow-up of 6.5 years reported that myeloablative AlloSCT achieved an overall survival of 40% but was associated with a high TRM. 17 A subsequent comparison of patient cohorts transplanted from 1983 to 1993 and from 1994 to 1998 showed that the TRM decreased from 46 to 30% 4 due to better patient selection, particularly transplantation in the earlier course of the disease. Subsequently, there were several reports from single centres indicating that with stringent patient selection better results could be obtained (Table 1 ). Two prospective, randomized studies have included a biological randomization to AlloSCT. In the US Intergroup S9321 study, patients were randomized to autologous SCT, chemotherapy or Cy/TBI ablative AlloSCT if a matched sibling was identified. The AlloSCT arm was closed early as a result of high TRM (53%). However, a subsequent analysis with a 7-year follow-up showed identical survival at 39%, with slightly superior PFS in the AlloSCT arm (22 vs 15%). There was also evidence of a plateau on the survival curve of the AlloSCT arm. 29 Similar results were obtained from a retrospective BSBMT (British Society of Blood and Marrow Transplantation) study of 139 patients under the age of 55 years, which showed superiority for Mel/TBI over Cy/TBI conditioning in both TRM and relapse rates. 18 In an attempt to reduce TRM and high incidence of GVHD, patients under the age of 55 years were entered into the HOVON 24 multiple myeloma study, who had an HLA-matched sibling who received a Cy/TBI T-cell depletion AlloSCT. 20 Patients without a sibling donor were randomized to receive a Cy/TBI allogeneic SCT (ASCT) or no further chemotherapy. Despite T-cell depletion, the TRM remained high at 34% and a high relapse rate with only 3 of 53 AlloSCT recipients in CR at a median followup of 38 months. The results of this study suggest that profound T-cell depletion should be avoided.
As a result of the experience of full-intensity AlloSCT, investigators explored the use of RIC AlloSCT in multiple myeloma, to reduce TRM and to permit the application of AlloSCT to older patients. Several studies have shown that this approach is feasible, with a significant reduction in TRM (Table 1) . By definition, in the absence of intensive chemo-radiotherapy, RIC AlloSCT is dependent to a large extent on allogeneic GvM effects. One strategy is to perform sequential ASCT/RIC AlloSCT such that minimal disease burden is present at the time of AlloSCT, thus allowing time for the allogeneic immune response to be effective. The Seattle group has studied this approach using sequential ASCT (Mel 200 ) followed by a T-replete, low-dose TBI-based RIC AlloSCT. 26 They report a day-100 TRM of 0% and 48-month overall survival and PFS of 69 and 45%, respectively. The incidence of grade 3-4 acute GVHD was 8% and that of chronic GVHD was 60%. Achievement of CR was often slow and coincident with the development of GVHD, though disease relapse remains an issue, even in the T-cell-replete protocols.
A number of phase II studies have reported similar findings. 22, 23, 30 In these studies, the presence of chronic GVHD was associated with the achievement of CR, and improved overall survival and PFS. In a retrospective EBMT study, the best outcomes of RIC AlloSCT were associated with the development of limited chronic GVHD. 31 The worst outcomes were seen in those patients who did not have any chronic GVHD and intermediate outcomes for those with extensive GVHD. In this analysis, the use of alemtuzamab was associated with significantly higher relapse rates. Taken together, these data suggest that a clinically effective GvM effect is intimately associated with chronic (not acute) GVHD, and that, by implication, strategies designed to abrogate GVHD, such as T-cell depletion, could have deleterious effects on disease control in this setting.
Two prospective, 'biologically randomized' studies of RIC AlloSCT have been published. IFM-99-03/04 enrolled patients with poor-risk disease as defined by the presence of del13 by FISH along with elevated b 2 -microglobulin (43 mg/l). 27 Those without a sibling donor received tandem ASCT, whereas those with a sibling donor received a sequential ASCT/RIC AlloSCT, the latter conditioning utilizing antigen thymocyte globulin (Genzyme, Haverhill, UK). This study showed no benefit in terms of overall survival/EFS and, indeed, no patients in either arm achieved durable EFS. Bruno et al. 24 reported on a group of unselected patients who were biologically randomized in a similar fashion to tandem ASCT or a sequential ASCT/ RIC AlloSCT. The RIC AlloSCT arm showed significantly superior overall survival/EFS. Two further similarly designed studies are yet to be reported (EBMT NMAM2000 and US Intergroup), and the role of a sequential Auto/RIC AlloSCT strategy in selected patients with multiple myeloma is yet to be proven. While no prospective trials have compared full-intensity with RIC AlloSCT in this setting, an EBMT analysis has shown similar overall survival using both approaches. As might be expected, RIC AlloSCT had a lower TRM but a higher relapse rate and lower PFS. 32 In general, outcomes with matched unrelated donor (MUD) AlloSCT have improved with time and, in many settings, have become equivalent to matched sibling transplantation. However, retrospective studies in myeloma have shown a significantly higher TRM than sibling AlloSCT, 33 and myeloablative MUD AlloSCT is currently not recommended and should only be carried out in the context of prospective clinical trials. However, the role of RIC MUD AlloSCT remains to be defined. Encouraging results have been reported, with a TRM of B20-21% at 2 and 3 years. 34, 35 Clearly, further prospective trials are warranted to define better the role of RIC MUD Allo SCT for patients with myeloma.
AlloSCT in multiple myeloma-clinical decision making
The treatment decision-making process involving the use of AlloSCT in the overall management strategy of patients with multiple myeloma represents some of the most difficult issues faced by haemato-oncology patients. Patients need to be fully informed of the risks and potential benefits of undergoing such a treatment; the clinical treatment strategy that is adopted should represent both the clinical evidence and the patient's understanding, and the informed consent.
The use of pre-transplant co-morbidity scoring systems has evolved in the SCT field, though these have yet to be validated in European populations and, specifically, their utility in a high-risk patient population, such as those with multiple myeloma, remains to be determined. Nonetheless, the use of either the co-morbidity system developed by Sorror et al. 36 encompassing cardiovascular, hepato-renal, respiratory and metabolic co-existing disease, or the system developed by Parimon and colleagues, 37 predominantly based on respiratory function estimates of survival, can be determined. Such systems may be developed in the future to be disease specific, permitting a more risk-adapted conditioning intensity strategy (see below), but clearly needs to be based on further retrospective analysis before this strategy could be applied in prospective clinical studies.
The published experience of AlloSCT in multiple myeloma has shown that treatment-related toxicities primarily relate to infection and end-organ damage, with incidences of acute and chronic GVHD similar to that of AlloSCT in other haematological malignancies. As such, a potential clinical decision-making tree is represented by the flow diagram illustrated in Figure 1 . Patients under 40 years of age with a matched sibling donor should be considered suitable for a full-intensity AlloSCT in the first treatment phase. Patients aged between 40-50 years may be considered suitable for a full-intensity matched related donor (MRD) AlloSCT based on their biological performance status, co-morbidity and disease-related features at the discretion of the transplant physician. The optimal conditioning regimen has never been prospectively compared, but retrospective analyses favour melphalan 140 mg/m 2 with fractionated TBI (12 Gy in 6 fractions). 18 In patients without a matched family donor, in the absence of a suitable clinical trial, 'standard' post-induction therapy is used, which is consolidation using high-dose chemotherapy and autologous stem cell re-infusion (ASCT). Whether a single ASCT or a double procedure is best is probably best determined by the depth of response to induction therapy, 5 and similarly the use of post-ASCT 'maintenance' therapy will be determined on the basis of whether a very good partial response or a better response is obtained.
No prospective trials have compared full-intensity with RIC Allo SCT in multiple myeloma, and the type of RIC regimen and therapy before it may matter. However, an EBMT analysis has shown similar overall survival using both approaches, though the RIC AlloSCT group had a lower TRM but a higher relapse rate and thus lower PFS. 32 This may reflect the heterogeneity of the patient populations, and further adaptation of RIC AlloSCT may be required to maximize the anti-tumour effect in association with the well-established reduced TRM. In patients over 40 years of age or in those deemed unfit for a full-intensity AlloSCT, RIC AlloSCT has been shown to reduce TRM. By definition, as full-intensity conditioning is not given, RIC transplants are dependent largely on the adoptive immunotherapeutic effect of GvM. As such, a 'tandem' sequential strategy has been developed to generate a minimal tumour burden before RIC AlloSCT using highdose melphalan-conditioned ASCT. A number of phase II studies have reported the feasibility and efficacy of such a strategy, especially in association with limited chronic GVHD. 22, 30, 32, 38 Bruno et al. 24 reported on a 'biologically randomized' study of sequential ASCT/RIC AlloSCT compared with double ASCT, showing a superior overall survival and EFS with the RIC AlloSCT arm. Two further studies are yet to be reported (EBMT NMAM2000, where a tandem ASCT followed by a MRD RIC AlloSCT is compared with double ASCT, and the US Intergroup). Therefore, in patients deemed to have adequate performance status or co-morbidity profile, the sequential ASCT and RIC AlloSCT may be a suitable therapeutic strategy to induce a minimal residual disease state (ASCT) on which to build the adoptive immunotherapeutic effect of GvM (RIC AlloSCT).
In light of the limitations in availability of a matched related (family) donor, alternative sourcing of donor stem cell grafts is routinely used in the management of acute and chronic myeloid malignancies. The use of matched volunteer donor (volunteer unrelated donor) grafts utilizing full-intensity conditioning is generally not supported even in younger patients in the first treatment phase. The improvement in volunteer unrelated donor full-intensity AlloSCT outcomes represents a future development but, at present, should only be considered as part of a clinical trial protocol (see also British Society for BMT indication table: http://www.bsbmt.org/cms_pages/64-Indications- Table) . 33 The role of RIC MUD AlloSCT remains to be defined although recent results have reported a TRM of B20%. 33, 34 Clearly, further prospective trials are warranted to better define the role of RIC MUD Allo SCT for patients in the first treatment phase for myeloma. Similarly, the use of umbilical cord stem cells as a source for GvM has been reported in a limited number of case reports, but only in patients with advanced disease, 39, 40 and again should be explored only as part of a clinical study protocol.
In the relapse/refractory setting, the outcome from AlloSCT has been reported to be inferior. 26 , 31 Corradini et al. 41 report that, for patients in first response, AlloSCT can induce CR in B60%, and that one-third of these patients will achieve a define persistent molecular remission. The achievement of a molecular CR is associated 
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G Cook et al with a very low risk of relapse. Though a prior ASCT is associated with a reduced overall survival when full-intensity AlloSCT is used in the relapse setting, this is not seen when RIC AlloSCT is used. 18, 32 A negative impact on the outcome is also seen with a prolonged time to transplant and with female donors for male recipients. The impact of cytogenetic abnormalities after AlloSCT remains to be determined, with the main issue being whether AlloSCT in molecularly high-risk multiple myeloma reduces the relapse risk to that of low-risk disease, as is seen in CLL. [42] [43] [44] Therefore, AlloSCT in relapsed multiple myeloma is best employed using a RIC protocol after maximum disease cytoreduction, and in this setting volunteer unrelated donor may be appropriate (Figure 1 ). It may be worth considering the pre-emptive therapy post-engraftment in relapsed patients to assist in the disease-eradicating effect of AlloSCT-derived GvM, especially in the presence of molecular/cytogenetic markers of high-risk disease.
Is AlloSCT the penultimate intervention? Post-AlloSCT therapy
Donor lymphocyte infusions from the original donor of the allograft are given for three main reasons: for relapse (which may be at various levels), pre-emptively in patients at high risk of relapse, and for correction of mixed chimerism in order to preserve a GvM effect and reduce the chance of relapse (reviewed by Tomblyn and Lazarus 45 ). There has been little work aimed at defining the main effector cells (T-cells or natural killer cells), and these may in fact vary from disease to disease. Little is known about the main 'antigenic' targets, and in multiple myeloma many immunotherapy trials have focussed on the multiple myeloma-specific idiotypic determinant of the Ig variable region though other antigenic determinants have been suggested, such as the cancer germline Ag. 46, 47 The available evidence suggests that the GvM effect is 'moderate', and that high doses of DLI resulting in clinical acute and chronic GVHD are required to achieve sustained disease responses. Extra-medullary plasmacytomas may be less susceptible to these immune attacks and may require separate therapy, such as radiotherapy.
Disease responses occur in about half of relapsed patients and up to 20% achieve CR. However, in the 54 patients reported by Lokhorst et al. 7 the median PFS was only 1.5 years. GVHD was the main predictor of response and occurred in more than half of the patients. Marrow aplasia was seen in nearly 20% of patients and may relate to the high initial T-cell doses used. In the Vancouver series 5 of 14 patients receiving DLI responded. 21 Zeiser et al. 48 reviewed the published myeloma DLI data in 2004. Overall 40-52% responded, with 25% having a CR. Response durations ranged from 6 to 15 months and responses were mainly seen after multiple DLI with high T-cell doses. Acute and chronic GVHD were seen in a half and a third, respectively.
Attempts to separate the GvM and GVHD effects have been made using CD8-depleted DLI. 49 Only one of nine patients who received 3 Â 10 7 CD3 þ cells/kg DLI had GVHD. Disease response data in patients with multiple myeloma using this approach are lacking and there is concern that reducing GVHD will also result in fewer patients responding.
Little is reported about the use of DLI to prevent relapse (in the absence of mixed chimerism) and also few data about its use to eliminate low-level MRD detected by molecular methods. Prophylactic DLI would be expected to have substantial toxicity. However, in the setting of reduced intensity conditioned AlloSCT, the use of DLI is quite different. When these regimens involve in vivo T-cell depletion using alemtuzamab or antigen thymocyte globulin, mixed chimerism is not an uncommon outcome and this may be associated with an increased risk of relapse. The University College London group reported 109 DLI in 46 patients (including 19 multiple myeloma patients) and a chimeric response in 30 of 35 patients. 50 GVHD was seen in 12 patients. Disease responses occurred in nearly two-thirds of multiple myeloma patients, though, surprisingly, they were not necessarily associated with chimeric responses. However, much investigation is required before we can confidently advise about the dose and timing of DLI, and each disease is likely to be different. 51, 52 Kroger 53 expresses the view that we should be targeting molecular remission and not settling for less rigorous assessments of disease. The shortcomings of these data have been noted (heterogeneity and short follow-up) and the need to do diseasespecific clinical trials have been promoted.
With the expansion of available biological therapies in the management of multiple myeloma, 54 the rationale for using such therapies post-AlloSCT has been proposed, either pre-emptively or to treat relapsing disease. 53 There is limited data regarding the use of bortezomib in this setting. In a small study, two cycles of four doses were completed by 14 patients, 55 with neurotoxicity and thrombocytopenia being the most frequently reported adverse events and in four patients there might have been some stimulation of GVHD. Nonetheless, complete and partial response rates of 30 and 50% were promising outcomes. An Italian series of 23 patients reported similar results, with 61% response and 22% immunofixation-negative CRs with a PFS of 6 months, though similar toxicities were seen in nearly onehalf of the cases. 56 In all 60% of these patients also received steroids, but this did not affect the response.
There are small series reporting the use of thalidomide post-AlloSCT. The IFM (Inter Groupe Franc¸ais du Myelome) group described 31 patients who received thalidomide (median dose 200 mg) as salvage for relapse post-allograft. 57 Nine patients responded (29%), with three PR and six very good partial response, though six patients required discontinuation (19%). Five developed GVHD. Kroger 58 gave low-dose thalidomide (100 mg) and DLI to 18 patients for progressive disease post-AlloSCT. Sixtyseven per cent responded, including 22% who had a CR. Weakness and peripheral neuropathy were the major toxicities seen. There was 84% 2-year PFS and a low incidence of GVHD. The pre-emptive use of thalidomide post-AlloSCT could also be used as 'maintenance/continuing' therapy similar to its use post-ASCT. [59] [60] [61] However, this potential benefit might be counterbalanced by its inhibition of GVHD and hence the GvM effect. In addition, its toxicity and effects on quality of life would also be unattractive in an allograft recipient. The combina-tion of bortezomib and thalidomide has been used in a small cohort of patients with relapsed multiple myeloma post-AlloSCT. 62 The authors evaluated DLIs given for relapsed (n ¼ 48) or persistent (n ¼ 15) multiple myeloma following RIC AlloSCT. Twenty-four (38.1%) of 63 patients responded to DLI. In all 15 (83.3%) of 18 patients not responding to (n ¼ 16) or relapsing (n ¼ 2) after DLI were sensitive to additional treatment with bortezomib and thalidomide. All seven patients treated with bortezomib responded, including two patients with a very good partial response. Six of nine patients achieved a PR after treatment with thalidomide (100-300 mg daily), and both the patients receiving both drugs achieved CR. In two patients treated with thalidomide, a transitory flare-up of GVHD was observed (one skin, one skin and liver).
Lenalidomide, developed as an analogue of thalidomide with immunomodulatory effects, has been shown to be efficacious in the management of multiple myeloma. 63, 64 However, there are fewer data concerning the use of lenalidomide in this situation. Studies are going on to determine the effect of post-AlloSCT administration of lenalidomide post-AlloSCT either as pre-emptive therapy or for early relapsing disease, and the efficacy of this strategy will be as important as the drug-related adverse events, especially the effect, if any, on GVHD.
The way forward-AlloSCT in the future
There is still scope for significant developments to maximize the potential of the GvM effect while minimizing the risk of AlloSCT. Much of the published work to date reporting on the effect of AlloSCT in multiple myeloma is based on chemotherapy. The impact of novel agents has been significant not only in terms of overall survival 10, 65 but also in terms of the depth of response to induction regimens. 66, 67 The depth of response before high-dose therapy influences the outcome, in the setting of ASCT. [68] [69] [70] In combination, these novel agents are able to induce major responses pretransplant, such that it may negate the need for a sequential high-dose approach required to obtain the chemotherapyinduced anti-tumour effect of the ASCT component of a tandem procedure. As such, it may be possible that the intensity of the AlloSCT regimen could be modified in line with risk stratification, as has been adopted in myeloid malignancies. Although speculative, it is tempting to propose that the greater response to induction regimens containing novel agents may improve the likelihood of success with rather than negating the need to proceed with AlloSCT.
Therefore, we should investigate whether by using novel induction agents in combination a CR could be obtained, followed by a multiple myeloma-specific risk-adjusted doseintensity-modified AlloSCT, for example, i.v. busulphan 0.8-3.6 mg/kg/day 73 with fludarabine 125 mg/m 2 .
(Though yet to be determined, several groups have started to address a risk-adjusted stratification in the overall design of antimyeloma therapy. 71, 72 ) Alternatively, a return to the use of radiation, to which multiple myeloma is sensitive, in the conditioning may be possible through novel strategies of delivering total marrow irradiation with limited end-organ exposure, such as image-guided marrow irradiation (helical tomotherapy) or radio-immunotherapy. 74, 75 The incorporation of radiation in an intensity-modulated fashion may be worth investigating to overcome the Allo-immune response in multiple myeloma G Cook et al adverse prognostic impact of molecular re-arrangements, for example, t(4;14), which to date has failed to improve with the incorporation of AlloSCT in the treatment pathway. 15 This coupled with pre-emptive post-engraftment disease modification, either through tumour-specific CTLs or through pulsed/sequential novel agents, could result in long-term disease control. A suggested clinical decision flow diagram is illustrated in Figure 2 , where the potent regimen of bortezomib, doxorubicin and dexamethasone could be used to capitalize on the response to a thalidomide-containing induction regimen for those who have not managed to attain a CR, before proceeding with AlloSCT. Clearly, this scheme represents a theoretical disease management strategy, but future clinical studies should address the role of AlloSCT in the context of new drug developments and clinical application of combination agents, if we are to maximize the effect on the tumour. The use of alternative sources of haematopoietic stem cells, in reference to umbilical cord units (UCB), may have significant limitations in multiple myeloma. One concern is the relative reduction in chronic GVHD compared with BM and PBSC stem cell collections, and given the evidence to support a correlation between cGVHD and GvM, concerns are raised as to whether the use of UCB units can truly provide us with the adoptive immunotherapy strategy required, especially with the absence of a post-graft preemptive or relapse immunotherapy option (DLI). Therefore, at present the use of UCB units in the treatment programme of patients with multiple myeloma should be reserved for well-designed clinical intervention protocols.
Conclusions
Although much has been learned by experience to date in the use of ASCT in the long-term management of multiple myeloma, its role in multiple myeloma is less certain than in other haematological malignancies, such as myeloid leukaemia. The over-arching premises of the putative GvM effect still remain elusive without considerable risk to the recipient. Nonetheless, even with all other therapy multiple myeloma is a universally fatal malignancy and although improvements have been made in overall survival by the introduction of new drugs, the median survival is still unacceptably short. With the introduction of novel agents, the potential to perform AlloSCT with considerably reduced tumour burdens, while permitting a more intensive conditioning regimen ('Mini, Midi, Maxi' 53 ) resulting from reduced pre-transplant endorgan therapy-related damage, encompasses the way forward. Furthermore, the AlloSCT should be viewed as the platform from which to launch a pre-emptive consolidative strategy to minimize the risk of disease relapse. This remains the challenge of the imminent future for the latter-day pioneers of AlloSCT medical practice.
